Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma

• Published in: Cancer cell Vol. 32; no. 6; pp. 856 - 868.e5
• Main Authors: Cosset, Érika, Ilmjärv, Sten, Dutoit, Valérie, Elliott, Kathryn, von Schalscha, Tami, Camargo, Maria F., Reiss, Alexander, Moroishi, Toshiro, Seguin, Laetitia, Gomez, German, Moo, Jung-Soon, Preynat-Seauve, Olivier, Krause, Karl-Heinz, Chneiweiss, Hervé, Sarkaria, Jann N., Guan, Kun-Liang, Dietrich, Pierre-Yves, Weis, Sara M., Mischel, Paul S., Cheresh, David A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 11.12.2017; Elsevier
• Subjects: Animals; Antineoplastic Agents - pharmacology; Brain Neoplasms - metabolism; Brain Neoplasms - mortality; cancer stem cells; Cell Line, Tumor; Gene Expression Profiling; glioblastoma; Glioblastoma - metabolism; Glioblastoma - mortality; glucose metabolism; Glucose Transporter Type 3 - metabolism; Glut3; Humans; integrin; Integrin alphaVbeta3 - metabolism; Kaplan-Meier Estimate; Life Sciences; Mice; Mice, Nude; Signal Transduction; Snake Venoms - pharmacology; Transcriptome; Xenograft Model Antitumor Assays; glioblastoma; cancer stem cells; Glut3; integrin; glucose metabolism

While molecular subtypes of glioblastoma (GBM) are defined using gene expression and mutation profiles, we identify a unique subpopulation based on addiction to the high-affinity glucose transporter, Glut3. Although Glut3 is a known driver of a cancer stem cell phenotype, direct targeting is complic...